EHT-102

N/A

Report date: 2026/04/15 20:02:38

Base Information

Drug NameEHT-102

Drug Alias NameEHT-102EHT-0102

ClassificationCell and gene therapy > Gene therapy

Mechanisms of ActionEpidermal growth factor receptor erbB1 agonistsEpidermal growth factor receptor erbB1 antagonistsAnticancer protein kinase inhibitors

TargetsEpidermal growth factor receptor erbB1

Therapy Area/IndicationsAutosomal recessive deafness-9Hearing LossOvarian Neoplasms +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFranceMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesDiaxonhit

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Youyin Pharmaceutical Biotechnology Co., Ltd.Shanghai Euhearing Therapeutics Co Ltd

Inactive CompaniesDiaxonhit

Active IndicationsAutosomal recessive deafness-9Hearing Loss

Inactive IndicationsOvarian NeoplasmsColonic NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A